Japan Radiotherapy Market Report 2022 to 2030

Japan Radiotherapy Market Analysis

$ 3999

By 2030, it is anticipated that the Japan Radiotherapy Market will reach a value of $711 Mn from $430 Mn in 2022, growing at a CAGR of 6.5% during 2022-30. The Radiotherapy Therapeutics Market in Japan is dominated by a few domestic players such as Hitachi, Mitsubishi Electric Corporation, and IHI Corporation. The radiotherapy market in Japan is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for Japan Radiotherapy is increasing on account of the rise in cancer cases in the country.

ID: IN10JPPH043 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Dr. Vishwa Modhia

Buy Now

Japan Radiotherapy Market Analysis Summary

By 2030, it is anticipated that the Japan Radiotherapy Market will reach a value of $711 Mn from $430 Mn in 2022, growing at a CAGR of 6.5% during 2022-30.

Japan is a high-income developed island nation in East Asia. Cancer treatment accounts for 7.3% of all healthcare resources. This is more prevalent in Japan than in other countries. Because of the country's large geriatric population, prostate and lung cancer medicines will dominate the Japanese cancer drug market in the next years. For more than 30 years, cancer has been the leading cause of death in Japan, and the mortality rate continues to grow year after year. Tobacco use has been linked to several cancers.

According to the Japanese Society for Radiation Oncology's 2017 Japanese Structure Survey of Radiation Oncology, radiation treatment was utilised to treat a total of 185,523 patients. In Japan, the population attributable fraction (PAF) of cigarette smoking to cancer was 24 %, infection was 22 %, alcohol drinking was 6 %, and salt over-consumption was 1.4 %. Japan's government spent 10.3% of its GDP on healthcare in 2020.

Japan Radiotherapy Market Analysis

Market Dynamics

Market Growth Drivers Analysis

Because of ongoing technology improvements and substantial capital expenditure, radiotherapy has been quickly evolving in Japan. The National Institutes for Quantum and Radiological Science and Technology (QST), and the National Institute of Radiological Sciences (NIRS), Japan, pioneered the use of carbon ions in heavy ion radiotherapy. From 1994 through the end of 2019, Japan's heavy ion radiation facilities successfully treated over 29,000 patients. These aspects could boost Japan's, Radiotherapy Market.

Market restraints

Japan had 1322 board-certified radiation oncologists and 1337 board-certified medical physicists as of 2021, however, there is still a considerable shortage of these specialists, particularly in small-scale facilities. Only 25-30% of cancer patients in Japan receive radiotherapy, which is nearly half the rate in nations with well-developed radiotherapy infrastructure in Europe and North America. Given this, the real number of teletherapy machines in Japan may be slightly in excess. The number of teletherapy equipment per centre in Japan was 1.24, making it the most dispersed among high-income countries. These factors may deter new entrants into the Japan Radiotherapy Market.

Competitive Landscape

Key Players

Hitachi: Hitachi is a leading Japanese multinational company that provides a range of medical equipment and services, including radiotherapy equipment
Mitsubishi Electric Corporation: Mitsubishi Electric is a Japanese company that offers advanced radiotherapy solutions, including linear accelerators and brachytherapy equipment
Toshiba Corporation: Toshiba is a Japanese multinational company that provides a range of medical equipment and services, including radiation therapy solutions
Shimadzu Corporation: Shimadzu is a Japanese company that offers radiation therapy equipment, including linear accelerators, brachytherapy equipment, and radiation measurement instruments
IHI Corporation: IHI is a Japanese company that provides radiotherapy equipment and solutions, including linear accelerators and proton therapy systems
Hamamatsu Photonics K.K.: Hamamatsu Photonics is a Japanese company that offers radiation measurement and monitoring equipment for radiation therapy

Healthcare Policies and Reimbursement Scenarios

In Japan, the regulations and reimbursement of radiotherapy are overseen by the Ministry of Health, Labour and Welfare (MHLW) and the Japan Health Insurance Association (JHIA). The MHLW also oversees the Japanese Society for Therapeutic Radiology and Oncology (JASTRO), which is the main professional organization for radiation oncologists in Japan. The JHIA is responsible for reimbursing the cost of radiotherapy for eligible patients under the national health insurance system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Radiotherapy Segmentation

By Type (Revenue, USD Billion):

External Beam Radiation Therapy
Linear Accelerators
Compact Advanced Radiotherapy Systems
Cyberknife
Gamma Knife
?Tomotherapy
Proton Therapy
Cyclotron
?Synchrotron
Internal Beam Radiation Therapy
Brachytherapy
Seeds
Applicators and Afterloaders
Electronic Brachytherapy
Systemic Radiation Therapy
?Others

?By Technology (Revenue, USD Billion):

External Beam Radiotherapy
Intensity-Modulated Radiation Therapy (IMRT)
Image-Guided Radiation Therapy (IGRT)
Stereotactic Radiation Therapy (SRT)
3D Conformal Radiation Therapy (3D-CRT)
Particle Therapy
Internal Beam Radiotherapy
Brachytherapy
High-Dose Rate Brachytherapy
Low-Dose Rate Brachytherapy
Image-Guided Brachytherapy
Pulse-Dose Rate Brachytherapy
Systemic Radiation Therapy
Intravenous Radiotherapy
Oral Radiotherapy?

By Application (Revenue, USD Billion):

Breast Cancer
Cervical Cancer
Colon and rectum Cancers
Stomach Cancer
Lung Cancer
Prostate Cancer
Skin Cancer
Liver Cancer
Other types of cancer

By End User (Revenue, USD Billion):

Hospitals
Radiotherapy Centers & Ambulatory Surgery Centers
?Cancer Research Institutes

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.